Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Chalasani

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Gastroenterology|December 28, 1999
Determinants of mortality in patients with advanced cirrhosis after transjugular intrahepatic portosystemic shuntingN Chalasani, W S Clark, L G Martin, et al.
Alimentary Pharmacology & Therapeutics|September 7, 2010
Duloxetine hepatotoxicity: a case-series from the drug-induced liver injury networkR Vuppalanchi, P H Hayashi, N Chalasani, et al.
The American Journal of Gastroenterology|November 24, 1999
Predictors of large esophageal varices in patients with cirrhosisN Chalasani, T F Imperiale, A Ismail, et al.
Alimentary Pharmacology & Therapeutics|March 10, 2012
Serum proteomic profiling in patients with drug-induced liver injuryL N Bell, R Vuppalanchi, P B Watkins, et al.
The American Journal of Gastroenterology|October 16, 1999
Screening for hepatocellular carcinoma in patients with advanced cirrhosisN Chalasani, J C Horlander, A Said, et al.
Journal of Vascular and Interventional Radiology : JVIR|November 8, 2001
Increase in hepatic arterial blood flow after transjugular intrahepatic portosystemic shunt creation and its potential predictive value of postprocedural encephalopathy and mortalityN H Patel, K J Sasadeusz, R Seshadri, et al.
Hepatology (Baltimore, Md.)|December 29, 1999
Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control studyN Chalasani, A Baluyut, A Ismail, et al.
Alimentary Pharmacology & Therapeutics|November 19, 2016
Improvement in liver histology due to lifestyle modification is independently associated with improved kidney function in patients with non-alcoholic steatohepatitisE Vilar-Gomez, L Calzadilla-Bertot, S L Friedman, et al.
Alimentary Pharmacology & Therapeutics|April 27, 2018
Randomised clinical trial: a leucine-metformin-sildenafil combination (NS-0200) vs placebo in patients with non-alcoholic fatty liver diseaseN Chalasani, R Vuppalanchi, M Rinella, et al.
Alimentary Pharmacology & Therapeutics|October 26, 2016
Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosisS A Harrison, S R Marri, N Chalasani, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Gastroenterology|December 28, 1999
Determinants of mortality in patients with advanced cirrhosis after transjugular intrahepatic portosystemic shuntingN Chalasani, W S Clark, L G Martin, et al.
Alimentary Pharmacology & Therapeutics|September 7, 2010
Duloxetine hepatotoxicity: a case-series from the drug-induced liver injury networkR Vuppalanchi, P H Hayashi, N Chalasani, et al.
The American Journal of Gastroenterology|November 24, 1999
Predictors of large esophageal varices in patients with cirrhosisN Chalasani, T F Imperiale, A Ismail, et al.
Alimentary Pharmacology & Therapeutics|March 10, 2012
Serum proteomic profiling in patients with drug-induced liver injuryL N Bell, R Vuppalanchi, P B Watkins, et al.
The American Journal of Gastroenterology|October 16, 1999
Screening for hepatocellular carcinoma in patients with advanced cirrhosisN Chalasani, J C Horlander, A Said, et al.
Journal of Vascular and Interventional Radiology : JVIR|November 8, 2001
Increase in hepatic arterial blood flow after transjugular intrahepatic portosystemic shunt creation and its potential predictive value of postprocedural encephalopathy and mortalityN H Patel, K J Sasadeusz, R Seshadri, et al.
Hepatology (Baltimore, Md.)|December 29, 1999
Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control studyN Chalasani, A Baluyut, A Ismail, et al.
Alimentary Pharmacology & Therapeutics|November 19, 2016
Improvement in liver histology due to lifestyle modification is independently associated with improved kidney function in patients with non-alcoholic steatohepatitisE Vilar-Gomez, L Calzadilla-Bertot, S L Friedman, et al.
Alimentary Pharmacology & Therapeutics|April 27, 2018
Randomised clinical trial: a leucine-metformin-sildenafil combination (NS-0200) vs placebo in patients with non-alcoholic fatty liver diseaseN Chalasani, R Vuppalanchi, M Rinella, et al.
Alimentary Pharmacology & Therapeutics|October 26, 2016
Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosisS A Harrison, S R Marri, N Chalasani, et al.
Pageof 5